These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 33776369)

  • 1. Genotype 3-hepatitis C virus' last line of defense.
    Zarębska-Michaluk D
    World J Gastroenterol; 2021 Mar; 27(11):1006-1021. PubMed ID: 33776369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rescue Therapy after Failure of HCV Antiviral Treatment with Interferon-Free Regimens.
    Tronina O; Brzdęk M; Zarębska-Michaluk D; Dybowska D; Lorenc B; Janczewska E; Mazur W; Parfieniuk-Kowerda A; Piekarska A; Krygier R; Klapaczyński J; Berak H; Jaroszewicz J; Garlicki A; Tomasiewicz K; Citko J; Flisiak R
    Viruses; 2023 Mar; 15(3):. PubMed ID: 36992388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease.
    Moser S; Kozbial K; Laferl H; Schütz A; Reiberger T; Schwabl P; Gutic E; Schwanke C; Schubert R; Luhn J; Lang T; Schleicher M; Steindl-Munda P; Haltmayer H; Ferenci P; Gschwantler M
    Eur J Gastroenterol Hepatol; 2018 Mar; 30(3):291-295. PubMed ID: 29120906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A decade of hepatitis C at the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa, in the pre-direct-acting antivirals era.
    Nordien R; Sonderup MW; Spearman CW
    S Afr Med J; 2020 Jan; 110(2):106-111. PubMed ID: 32657679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era.
    Brzdęk M; Zarębska-Michaluk D; Rzymski P; Lorenc B; Kazek A; Tudrujek-Zdunek M; Janocha-Litwin J; Mazur W; Dybowska D; Berak H; Parfieniuk-Kowerda A; Klapaczyński J; Sitko M; Sobala-Szczygieł B; Piekarska A; Flisiak R
    World J Gastroenterol; 2023 Apr; 29(13):2015-2033. PubMed ID: 37155527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure.
    Lu M; Wu KH; Li J; Moorman AC; Spradling PR; Teshale EH; Boscarino JA; Daida YG; Schmidt MA; Rupp LB; Zhang T; Trudeau S; Gordon SC
    J Viral Hepat; 2019 Oct; 26(10):1210-1217. PubMed ID: 31197910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
    Asselah T; Marcellin P
    Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C.
    Brzdęk M; Zarębska-Michaluk D; Invernizzi F; Cilla M; Dobrowolska K; Flisiak R
    World J Gastroenterol; 2023 Feb; 29(6):949-966. PubMed ID: 36844142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of IL28B for chronic hepatitis C treatment toward personalized medicine.
    Matsuura K; Watanabe T; Tanaka Y
    J Gastroenterol Hepatol; 2014 Feb; 29(2):241-9. PubMed ID: 24325405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Closing the Gap: The Challenges of Treating Hepatitis C Virus Genotype 3 Infection.
    Martin MT; Deming P
    Pharmacotherapy; 2017 Jun; 37(6):735-747. PubMed ID: 28374965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.
    Chayama K; Takahashi S; Toyota J; Karino Y; Ikeda K; Ishikawa H; Watanabe H; McPhee F; Hughes E; Kumada H
    Hepatology; 2012 Mar; 55(3):742-8. PubMed ID: 21987462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals.
    Coppola N; Pisaturo M; Zampino R; Macera M; Sagnelli C; Sagnelli E
    World J Gastroenterol; 2015 Oct; 21(38):10749-59. PubMed ID: 26478667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The hepatitis C revolution part 1: antiviral treatment options.
    Thiagarajan P; Ryder SD
    Curr Opin Infect Dis; 2015 Dec; 28(6):563-71. PubMed ID: 26524328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel therapeutic approaches for hepatitis C.
    Au JS; Pockros PJ
    Clin Pharmacol Ther; 2014 Jan; 95(1):78-88. PubMed ID: 24126682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How to optimize current therapy in hepatitis C virus genotype 1 patients. Predictors of response to interferon-based therapy with second wave direct acting antivirals.
    Serfaty L
    Liver Int; 2015 Jan; 35 Suppl 1():18-20. PubMed ID: 25529083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does a detectable HCV RNA at the end of DAA therapy herald treatment failure?
    Zarębska-Michaluk D; Flisiak R; Janczewska E; Berak H; Mazur W; Janocha-Litwin J; Krygier R; Dobracka B; Jaroszewicz J; Parfieniuk-Kowerda A; Dobrowolska K; Rzymski P
    Antiviral Res; 2023 Dec; 220():105742. PubMed ID: 37944825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical features and treatment outcome of chronic hepatitis C with pegylated interferon and ribavirin in routine care.
    Tan SS; Adlin Nadia Z
    Med J Malaysia; 2017 Jun; 72(3):165-174. PubMed ID: 28733564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment failure with new hepatitis C drugs.
    Soriano V; Vispo E; Poveda E; Labarga P; Barreiro P
    Expert Opin Pharmacother; 2012 Feb; 13(3):313-23. PubMed ID: 22242928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
    Manns MP; Markova AA; Calle Serrano B; Cornberg M
    Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct-acting antiviral therapy for hepatitis C: The initial experience of the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa.
    Sonderup MW; Gogela N; Nordien R; Smuts H; Korsman S; Hardie D; Spearman CW
    S Afr Med J; 2020 Jan; 110(2):112-117. PubMed ID: 32657680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.